Mayne Pharma Group Limited's latest marketcap:
As of 08/11/2025, Mayne Pharma Group Limited's market capitalization has reached $263.85 M. According to our data, Mayne Pharma Group Limited is the 18695th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 263.85 M |
| Revenue (ttm) | 269.12 M |
| Net Income (ttm) | -84,100,280.8 |
| Shares Out | 81.25 M |
| EPS (ttm) | -1.07 |
| Forward PE | 0.00 |
| Ex-Dividend Date | 01/18/2023 |
| Earnings Date | 08/25/2025 |
Mayne Pharma Group Limited's yearly market capitalization.
| Date | Market Cap(A$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/11/2025 | A$405.42 M | $263.85 M | 0.4% | 18695 |
| 12/31/2024 | A$403.79 M | $249.81 M | -19.19% | 17592 |
| 12/29/2023 | A$499.66 M | $340.16 M | 43.6% | 15609 |
| 12/30/2022 | A$347.96 M | $237.05 M | -33.16% | 17025 |
| 12/31/2021 | A$520.63 M | $377.71 M | -10.12% | 15083 |
| 12/31/2020 | A$579.28 M | $445.69 M | -20.69% | 12231 |
| 12/31/2019 | A$730.39 M | $512.37 M | -40.46% | 9919 |
| 12/31/2018 | A$1.23 B | $864.63 M | 14.49% | 6659 |
| 12/29/2017 | A$1.07 B | $836.66 M | -46.85% | 7951 |
| 12/30/2016 | A$2.02 B | $1.45 B | 77.16% | 5017 |
Company Profile
Mayne Pharma Group Limited Overview
Mayne Pharma Group Limited is a specialty pharmaceutical company engaged in the manufacturing and sale of branded and generic pharmaceutical products across multiple regions, including:
- Australia
- New Zealand
- United States
- Canada
- Europe
- Asia
- Other international markets
Business Segments
The company operates through three key segments:
- Women’s Health
- Dermatology
- International
Products and Services
Mayne Pharma offers:
- Oral drug delivery systems
- Contract development and manufacturing services for third-party customers
- Distribution of specialty pharmaceutical products in therapeutic areas such as dermatology, women’s health, and infectious diseases
Company Background
Originally named Halcygen Pharmaceuticals Limited, the company rebranded to Mayne Pharma Group Limited in November 2010. Founded in 2005, it is headquartered in Salisbury South, Australia.
Frequently Asked Questions
-
What is Mayne Pharma Group Limited's (ASX-MYX) current market cap?As of 08/11/2025, Mayne Pharma Group Limited (including the parent company, if applicable) has an estimated market capitalization of $263.85 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Mayne Pharma Group Limited (ASX-MYX) rank globally by market cap?Mayne Pharma Group Limited global market capitalization ranking is approximately 18695 as of 08/11/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.